Cell & Gene Exchange, May 2017: Asymmetrex, LLC

June 16, 2017
Asymmetrex is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s rich patent portfolio contains biotechnologies that solve the two main technical problems—production and quantification—that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. Currently, Asymmetrex’s main business development focus is increasing adoption of its contract service for specific counting of adult tissue stem cells. The company’s first-in-kind AlphaSTEM Test technology combines stem cell kinetics and computer simulation to determine previously inaccessible cell kinetics properties of tissue stem cells, including their number, cell cycle time, self-renewal rate, and death rate. Thus, the AlphaSTEM Test can be used to determine the stem cell-specific dose of stem cell transplant treatments for the first time, as well as provide a quality control test for tissue stem cell preparations in general. Speaker: James Sherley – Director
Previous Video
Cell & Gene Exchange, May 2017: Research Cancer Institute of America/Pacific Medical Center of Hope
Cell & Gene Exchange, May 2017: Research Cancer Institute of America/Pacific Medical Center of Hope

Research Cancer Institute of America (RCIA) has established a novel concept and team of scientific experts ...

Next Video
Cell & Gene Exchange, May 2017: Alliance for Regenerative Medicine Annual Dinner and Program
Cell & Gene Exchange, May 2017: Alliance for Regenerative Medicine Annual Dinner and Program

ARM’s Annual Dinner is one of the regenerative medicine and advanced therapies sector’s premier events. Thi...